Stocks Health care FLGT
NASDAQ · Health careFulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. brought in $323.9M of revenue over the twelve months to June 30, 2026, up 6.8% from a year earlier. It posted a net loss of $84.4M. In fiscal 2025 capital spending exceeded operating cash flow by $124.2M. At June 30, 2026 it held $26.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Fulgent Genetics, Inc. does
Fulgent Genetics, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker FLGT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $322.7M | -$60.5M | n/a | -$124.2M |
| 2024 | $283.5M | -$42.7M | n/a | -$19.3M |
| 2023 | $289.2M | -$167.8M | n/a | $4.8M |
| 2022 | $619M | $143.4M | n/a | $234.7M |
| 2021 | $992.6M | $507.4M | n/a | $514.8M |
| 2020 | $421.7M | $214.3M | n/a | $105.5M |
Latest SEC filings
What Fulgent Genetics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- June 2, 2026Other event 8-K
- May 27, 2026Activist stake changed SCHEDULE 13D/A
- May 21, 2026Other event 8-K
- May 14, 2026
- May 14, 2026
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026
- May 1, 2026
- March 31, 2026Activist stake changed SCHEDULE 13D/A
Questions about FLGT
What does Fulgent Genetics, Inc. do?
Fulgent Genetics, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker FLGT.
Is Fulgent Genetics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $84.4M on revenue of $323.9M.
How much revenue does Fulgent Genetics, Inc. make?
Over the twelve months to June 30, 2026 Fulgent Genetics, Inc. reported revenue of $323.9M. That is 6.8% more than a year earlier.
When did Fulgent Genetics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Follow FLGT
Get an email when Fulgent Genetics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FLGT: get an email when it filesWhere the numbers come from
Financial figures are the values Fulgent Genetics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.